The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.
BACKGROUND
This study was designed to investigate, for the first time, the short-term molecular evolution of the HIV-2 C2, V3 and C3 envelope regions and its association with the immune response. Clonal sequences of the env C2V3C3 region were obtained from a cohort of eighteen HIV-2 chronically infected patients followed prospectively during 2-4 years. Genetic diversity, divergence, positive selection and glycosylation in the C2V3C3 region were analysed as a function of the number of CD4+ T cells and the anti-C2V3C3 IgG and IgA antibody reactivity


RESULTS
The mean intra-host nucleotide diversity was 2.1% (SD, 1.1%), increasing along the course of infection in most patients. Diversity at the amino acid level was significantly lower for the V3 region and higher for the C2 region. The average divergence rate was 0.014 substitutions/site/year, which is similar to that reported in chronic HIV-1 infection. The number and position of positively selected sites was highly variable, except for codons 267 and 270 in C2 that were under strong and persistent positive selection in most patients. N-glycosylation sites located in C2 and V3 were conserved in all patients along the course of infection. Intra-host variation of C2V3C3-specific IgG response over time was inversely associated with the variation in nucleotide and amino acid diversity of the C2V3C3 region. Variation of the C2V3C3-specific IgA response was inversely associated with variation in the number of N-glycosylation sites.


CONCLUSIONS
The evolutionary dynamics of HIV-2 envelope during chronic aviremic infection is similar to HIV-1 implying that the virus should be actively replicating in cellular compartments. Convergent evolution of N-glycosylation in C2 and V3, and the limited diversification of V3, indicates that there are important functional constraints to the potential diversity of the HIV-2 envelope. C2V3C3-specific IgG antibodies are effective at reducing viral population size limiting the number of virus escape mutants. The C3 region seems to be a target for IgA antibodies and increasing N-linked glycosylation may prevent HIV-2 envelope recognition by these antibodies. Our results provide new insights into the biology of HIV-2 and its relation with the human host and may have important implications for vaccine design.
Borrego
Pedro
P
URIA-CPM, Faculdade de Farmácia de Lisboa, Avenida das Forças Armadas, 1649-019 Lisbon, Portugal. pborrego@ff.ul.pt
Marcelino
José Maria
JM
Rocha
Cheila
C
Doroana
Manuela
M
Antunes
Francisco
F
Maltez
Fernando
F
Gomes
Perpétua
P
Novo
Carlos
C
Barroso
Helena
H
Taveira
Nuno
N
D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D019143:Evolution, Molecular; D006031:Glycosylation; D015483:HIV Antibodies / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000235:genetics* / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000821:virology*; D015498:HIV-2 / Q000235:genetics* / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D008137:Longitudinal Studies; D008969:Molecular Sequence Data; D011110:Polymorphism, Genetic; D011499:Protein Processing, Post-Translational; D012641:Selection, Genetic; D017422:Sequence Analysis, DNA
D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D007070:Immunoglobulin A; D007074:Immunoglobulin G; C514796:gp120 protein, Human immunodeficiency virus 2
J Virol. 2000 May;74(9):4335-50
10756049
Infect Genet Evol. 2005 Apr;5(3):239-46
15737915
AIDS Rev. 2006 Jul-Sep;8(3):125-40
17078483
J Virol. 2008 Apr;82(8):3952-70
18256145
JAMA. 1996 Jan 17;275(3):210-6
8604174
AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1307-12
10957727
Bioinformatics. 1998;14(9):817-8
9918953
J Infect Dis. 2007 Mar 1;195(5):726-33
17262716
Bioinformatics. 2005 Mar 1;21(5):676-9
15509596
AIDS Res Hum Retroviruses. 2004 Dec;20(12):1373-6
15650432
J Hum Virol. 1998 Nov-Dec;1(7):457-68
10195267
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12568-73
9770526
J Virol. 2006 Dec;80(24):12425-9
17035326
AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1167-73
12487822
Virology. 1999 Nov 10;264(1):237-43
10544150
Arch Intern Med. 2000 Nov 27;160(21):3286-93
11088091
J Virol. 1996 Oct;70(10):7143-52
8794361
J Mol Evol. 2003 Aug;57(2):212-21
14562964
J Gen Virol. 2005 Dec;86(Pt 12):3385-3396
16298986
J Virol. 2007 May;81(10):5325-30
17329334
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
12644702
J Med Virol. 2000 May;61(1):111-6
10745242
Mol Biol Evol. 2003 Aug;20(8):1318-25
12777505
J Mol Evol. 1981;17(6):368-76
7288891
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18514-9
16339909
Mol Biol Evol. 2005 Mar;22(3):456-68
15509726
J Gen Virol. 2002 Jun;83(Pt 6):1253-1265
12029140
Virology. 2006 Sep 15;353(1):144-54
16814357
J Virol. 2004 Feb;78(4):1962-70
14747561
Retrovirology. 2005 Nov 07;2:67
16274482
Lancet. 1994 Apr 16;343(8903):943-6
7909009
Science. 1994 Sep 9;265(5178):1587-90
7915856
J Gen Virol. 2006 Feb;87(Pt 2):411-418
16432029
J Infect Dis. 2007 Jul 15;196(2):313-20
17570120
Glycobiology. 2004 Dec;14(12):1229-46
15175256
Science. 2004 Jan 16;303(5656):327-32
14726583
AIDS Res Hum Retroviruses. 2007 Oct;23(10):1242-50
17961111
Retrovirology. 2005 Jun 29;2:41
15985187
J Virol. 2008 Feb;82(4):1860-9
18057243
AIDS Res Hum Retroviruses. 2004 Dec;20(12):1314-23
15650424
J Virol. 2007 May;81(10):5331-8
17301136
J Virol. 2002 Nov;76(22):11715-20
12388731
Hum Antibodies. 2005;14(3-4):69-72
16720976
Nat Rev Immunol. 2004 Mar;4(3):199-210
15039757
J Clin Microbiol. 2007 May;45(5):1572-80
17329448
J Gen Virol. 2006 Mar;87(Pt 3):607-612
16476981
Nature. 2003 Mar 20;422(6929):307-12
12646921
AIDS. 1994 Nov;8(11):1617-20
7848600
AIDS Res Hum Retroviruses. 1995 May;11(5):617-23
7576918
J Virol. 1997 Oct;71(10):7719-27
9311856
Virology. 1993 Mar;193(1):528-30
8438591
Mol Biol Evol. 2007 Aug;24(8):1596-9
17488738
J Virol. 1997 Oct;71(10):7498-508
9311829
PLoS Comput Biol. 2007 Feb 16;3(2):e29
17305421
J Clin Microbiol. 1999 Feb;37(2):453-6
9889242
J Virol. 1994 Nov;68(11):7467-81
7933130
J Virol. 1992 Nov;66(11):6777-80
1404617
J Clin Microbiol. 2006 Feb;44(2):607-11
16455923
J Virol. 1998 Apr;72(4):3418-22
9525673
J Virol. 1999 Dec;73(12):10489-502
10559367
Science. 2005 Nov 11;310(5750):1025-8
16284180
J Virol. 2004 Jul;78(13):7016-22
15194778
Evolution. 1985 Jul;39(4):783-791
28561359
J Immunol. 1991 Nov 1;147(9):3128-32
1717587
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1264-9
9037041
Viral Immunol. 2004;17(3):436-9
15357909
Virology. 2003 Apr 10;308(2):225-32
12706073
J Biol Chem. 2001 Apr 20;276(16):13433-41
11278567
Nucleic Acids Res. 1997 Dec 15;25(24):4876-82
9396791
J Virol. 2006 Oct;80(19):9586-98
16973562
Nat Rev Genet. 2004 Jan;5(1):52-61
14708016
Clin Exp Immunol. 1999 Jun;116(3):474-8
10361237
Nature. 2007 Apr 26;446(7139):1038-45
17460665
Virology. 2002 Dec 5;304(1):70-80
12490404
PLoS Comput Biol. 2007 Jan 19;3(1):e11
17238283